Published in

American Society of Hematology, Blood, 22(134), p. 1951-1959, 2019

DOI: 10.1182/blood.2019001077

Links

Tools

Export citation

Search in Google Scholar

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Journal article published in 2019 by Philip A. Thompson ORCID, Jaya Srivastava, Christine Peterson ORCID, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger ORCID, Zeev Estrov ORCID, Nitin Jain, William G. Wierda
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Thompson and colleagues report that detection of minimal residual disease using next-generation sequencing, which is 2 orders of magnitude more sensitive than flow cytometry, is a much better predictor of progression-free survival.